4.8 Article

An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development

Journal

NATURE MEDICINE
Volume 21, Issue 12, Pages 1445-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3982

Keywords

-

Funding

  1. US National Institutes of Health [R01NS083823]
  2. Simons Foundation for Autism Research [275275]
  3. Howard Hughes Medical Institute
  4. National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behavior Research Foundation [22892]
  5. Human Frontier Science Program Long-Term Fellowship
  6. A.P. Giannini Foundation Fellowship
  7. NIH NICHD K99/R00 Pathway to Independence Award [K99HD082337]
  8. Dr. Alfonsina Q. Davies Endowed Chair in honor of Paul Crandall MD

Ask authors/readers for more resources

Focal malformations of cortical development (FMCDs) account for the majority of drug-resistant pediatric epilepsy. Postzygotic somatic mutations activating the phosphatidylinositol-4,5-bisphosphate-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway are found in a wide range of brain diseases, including FMCDs. It remains unclear how a mutation in a small fraction of cells disrupts the architecture of the entire hemisphere. Within human FMCD-affected brain, we found that cells showing activation of the PI3K-AKT-mTOR pathway were enriched for the AKT3(E17K) mutation. Introducing the FMCD-causing mutation into mouse brain resulted in electrographic seizures and impaired hemispheric architecture. Mutation-expressing neural progenitors showed misexpression of reelin, which led to a non-cell autonomous migration defect in neighboring cells, due at least in part to derepression of reelin transcription in a manner dependent on the forkhead box (FOX) transcription factor FOXG1. Treatments aimed at either blocking downstream AKT signaling or inactivating reelin restored migration. These findings suggest a central AKT-FOXG1-reelin signaling pathway in FMCD and support pathway inhibitors as potential treatments or therapies for some forms of focal epilepsy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available